Skip to main content

StoneX Group Inc. Acquires Advanced Marketing Group, Expanding Its Feed Ingredients Trading Capabilities

Acquisition extends StoneX Supply & Trading into animal-protein feed ingredients, pet food, and organic fertilizer across North America  NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) — StoneX Group Inc. (“StoneX”: NASDAQ: SNEX) announced today that it has acquired Advanced Marketing Group, LLC (“AMG”), a merchandiser of ingredients for feed, pet food ingredients, and organic fertilizer. The business will be integrated into StoneX Supply & Trading’s feed ingredients capabilities. Founded in 2010 and headquartered in Wilsonville, Oregon, AMG trades animal protein-based feed ingredients and manufactures organic fertilizers, serving pet-food manufacturers, dairy and poultry producers, feed mills, feedlots, and fertilizer brands. AMG’s roughly 20 trading and operations professionals operate in four U.S. states...

Continue reading

Form-8.3 APTITUDE SOFTWARE GROUP PLC – 18 08 2026 – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree APTITUDE SOFTWARE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: APTITUDE...

Continue reading

Form-8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC – 18 08 2026 – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Man Group PLC : Form 8.3 – Rotork plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Man Group PLC(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Rotork Plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position disclosure,...

Continue reading

Evolution Petroleum Announces Strategic Midland Basin Mineral & Royalty Acquisition

HOUSTON, Aug. 18, 2026 (GLOBE NEWSWIRE) — Evolution Petroleum Corporation (NYSE American: EPM) (“Evolution” or the “Company”) has entered into a definitive agreement to acquire mineral and royalty (“M&R”) interests in the core Midland Basin of the Permian Basin from a non-affiliated private seller for a total purchase price of approximately $16 million (the “Acquisition”), subject to customary adjustments and closing conditions. The Acquisition is expected to close on or about August 21, 2026, and has an effective date of August 1, 2026 (the “Effective Date”). As of the Effective Date, the Acquisition interests span approximately 3,420 net royalty acres across Reagan, Upton, Glasscock, Midland, and Martin Counties, Texas. Evolution expects to fund the Acquisition with...

Continue reading

Schouw & Co. exceeds the 10% threshold of treasury shares

In accordance with Section 31 of the Danish Capital Markets Act, it is hereby announced that on 18 August 2026, Schouw & Co. crossed the 10% threshold of the company’s treasury shares as part of its ongoing share buy-back programme. Following the transaction, Schouw & Co. holds a total of 2,504,076 treasury shares, corresponding to 10.02% of the total share capital and 10.02% of the total voting rights. The voting rights attached to the treasury shares cannot be exercised at the company’s general meetings. The ongoing share buy-back programme will continue in accordance with the previously announced terms and conditions. Aktieselskabet Schouw & Co. Jørgen Wisborg, Chairman of the Board of Directors Jens Bjerg Sørensen, President & CEO Please direct any questions to President Jens Bjerg Sørensen, telephone no. +45 86...

Continue reading

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Acquisition expands Cellution Biologics’ human tissue-based portfolio and marks its entry into the U.S. reconstructive surgery market ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) — Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT). The acquisition marks Cellution Biologics’ entry into the U.S. reconstructive surgery market, adding a new surgical category to its existing portfolio across wound care, ocular repair and other surgical applications. SimpliDerm is an established human acellular dermal matrix with a proven commercial presence in the U.S....

Continue reading

Cint Enters New Phase of Growth and Innovation Under Private Ownership

Company to accelerate investment across research, media measurement, data and AI while maintaining a continued focus on trusted human intelligence NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) — Cint, the global technology company behind continuous research and media measurement, today announces the completion of the take-private transaction, signaling the beginning of a new phase for the company focused on accelerating innovation and investment across its research, media measurement, data, and artificial intelligence capabilities. The transition follows the public cash offer for Cint Group AB by TriCarbs BidCo AB, a bid vehicle backed by Triton Fund 6 and Bolero Holdings SARL in a consortium led by Triton Partners. The last day of trading in Cint shares on Nasdaq Stockholm was 7 August 2026. “Cint has always been built around a simple...

Continue reading

R1 to Acquire Humata Health, Enhancing Phare OS with AI-Powered Prior Authorization Automation and Payer-Provider Collaboration

Acquisition Removes Friction from Complex Prior Authorizations to Benefit Patients, Clinicians, Providers, and Payers CHICAGO, Aug. 18, 2026 (GLOBE NEWSWIRE) — R1 (“R1” or the “Company”), an industry leader in healthcare revenue management, today announced that it has entered into an agreement to acquire Humata Health (“Humata”), a leader in AI-powered, touchless prior authorizations. The transaction marks a significant step in advancing R1’s strategy to comprehensively automate the revenue cycle through its Phare Operating System (“Phare OS”), expanding the platform’s AI-powered capabilities while helping providers reduce administrative complexity, increase reimbursement accuracy, and improve financial outcomes. Prior authorizations are a top-three driver of denials and a frequent source of frustration for health systems, clinicians,...

Continue reading

Acorn Secures 100% Ownership of OmniMetrix Subsidiary via Purchase of Remaining 1% Stake

WILMINGTON, Del., Aug. 18, 2026 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for critical infrastructure, announced that it has acquired the remaining outstanding 1% ownership interest in OmniMetrix, its principal operating subsidiary, bringing Acorn’s ownership to 100%. The interest was acquired from OmniMetrix’ former CEO, Walter Czarnecki, in exchange for 25,096 newly-issued shares of Acorn common stock, a number of shares equal to approximately 1% of Acorn’s shares outstanding immediately prior to the transaction. Following the exchange, Acorn has 2,534,714 shares outstanding. The transaction streamlines OmniMetrix’s ownership structure and will simply Acorn’s financial reporting by eliminating the non-controlling interest deductions from Acorn’s net income and increasing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.